Alpha Teknova, Inc. (TKNO): Teknova Reports Third Quarter 2026 Financial Results
Alpha Teknova, Inc. (TKNO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Teknova Reports Third Quarter 2026 Financial Results Third quarter 2026 total revenue was $12.7 million, up 22% over the same quarter prior year Company raises 2026 revenue guidance to $46-48 million Strengthened balance sheet with $46 million public equity offering
How this was made
The 30-second read
Why it matters
The raised guidance signals stronger demand for its custom reagents, potentially expanding its market share in biotech and diagnostics.
Market read
The fresh guidance lift is a primary disclosure for a micro‑cap biotech supplier, offering a clear catalyst for short‑term price movement.
What to watch
The company still posted a net loss and negative adjusted EBITDA, which may temper enthusiasm.
Third quarter 2026 total revenue was $12.7 million, up 22% over the same quarter prior year; company raises 2026 revenue guidance to $46-48 million.
Revenue grew 22%, gross margin improved to 38.0% from 30.7%, net loss and Adjusted EBITDA losses narrowed, and Free Cash Outflow declined. The company raised revenue guidance while reaffirming Free Cash Outflow guidance, although it remained loss-making and operating expenses increased.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total revenue, three months ended September 30, 2026GAAP | $12.70M | – | 22% |
| Cost of sales, three months ended September 30, 2026GAAP | 7,878 | – | – |
| Gross profit, three months ended September 30, 2026GAAP | $4.83M | – | – |
| Gross margin, three months ended September 30, 2026GAAP | 38.0% | – | – |
| Research and development expense, three months ended September 30, 2026GAAP | 581 | – | – |
| Sales and marketing expense, three months ended September 30, 2026GAAP | 2,348 | – | – |
| General and administrative expense, three months ended September 30, 2026GAAP | 4,816 | – | – |
| Amortization of intangible assets, three months ended September 30, 2026GAAP | 287 | – | – |
| Total operating expenses, three months ended September 30, 2026GAAP | 8,032 | – | – |
| Loss from operations, three months ended September 30, 2026GAAP | (3,206) | – | – |
| Interest expense, net, three months ended September 30, 2026GAAP | (259) | – | – |
| Other income, three months ended September 30, 2026GAAP | 9 | – | – |
| Total other expenses, net, three months ended September 30, 2026GAAP | (250) | – | – |
| Loss before income taxes, three months ended September 30, 2026GAAP | (3,456) | – | – |
| Provision for income taxes, three months ended September 30, 2026GAAP | 34 | – | – |
| Net loss, three months ended September 30, 2026GAAP | −$3.49M | – | – |
| Net loss per share, basic and diluted, three months ended September 30, 2026GAAP | $ (0.06) | – | – |
| Weighted average shares used in computing net loss per share, basic and diluted, three months ended September 30, 2026GAAP | 53,694,378 | – | – |
| Adjusted EBITDA, three months ended September 30, 2026non-GAAP | −$996K | – | – |
| Cash used in operating activities, three months ended September 30, 2026GAAP | −$1.28M | – | – |
| Purchases of property, plant, and equipment, three months ended September 30, 2026GAAP | (120) | – | – |
| Free Cash Flow, three months ended September 30, 2026non-GAAP | −$1.40M | – | – |
| Total revenue, nine months ended September 30, 2026GAAP | $35.97M | – | – |
| Gross profit, nine months ended September 30, 2026GAAP | $13.49M | – | – |
| Total operating expenses, nine months ended September 30, 2026GAAP | 23,889 | – | – |
| Loss from operations, nine months ended September 30, 2026GAAP | (10,394) | – | – |
| Net loss, nine months ended September 30, 2026GAAP | −$11.21M | – | – |
| Net loss per share, basic and diluted, nine months ended September 30, 2026GAAP | $ (0.21) | – | – |
| Adjusted EBITDA, nine months ended September 30, 2026non-GAAP | −$3.69M | – | – |
| Cash used in operating activities, nine months ended September 30, 2026GAAP | −$5.11M | – | – |
| Free Cash Flow, nine months ended September 30, 2026non-GAAP | −$5.57M | – | – |
| Cash and cash equivalents, as of September 30, 2026GAAP | $6.63M | – | – |
| Short-term investments, held-to-maturity, as of September 30, 2026GAAP | 9,929 | – | – |
| Total cash and short-term investments, at the end of the third quarter 2026GAAP | $16.6M | – | – |
| Long-term debt, net, as of September 30, 2026GAAP | 13,269 | – | – |
| Total borrowings, at the end of the third quarter 2026GAAP | $13.2M | – | – |
| Total assets, as of September 30, 2026GAAP | $94.68M | – | – |
| Total liabilities, as of September 30, 2026GAAP | 34,900 | – | – |
| Total stockholders’ equity, as of September 30, 2026GAAP | 59,784 | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Lab Essentials, three months ended September 30, 2026Not separately discussed. | $9.03M | – | 9% |
| Clinical Solutions, three months ended September 30, 2026Not separately discussed. | 3.17M | – | 86% |
| Other, three months ended September 30, 2026Not separately discussed. | 502 | – | – |
| Lab Essentials, nine months ended September 30, 2026Not separately discussed. | $26.61M | – | – |
| Clinical Solutions, nine months ended September 30, 2026Not separately discussed. | 7.74M | – | – |
| Other, nine months ended September 30, 2026Not separately discussed. | 1.61M | – | – |
Fiscal year ending December 31, 2026 outlook
- Revenue$46 million to $48 million
- NoteFree Cash Outflow of less than $8 million
What drove it
- Growth was driven by increased sales of products to life science tools and diagnostics, and to biopharma customers.
- The company cited an increase in purchases of custom products by small and mid-sized biotech customers and their associated contract manufacturers.
- Gross-margin improvement was primarily driven by higher revenue and, to a lesser extent, lower fixed cost absorption into cost of goods sold from changes in finished goods inventory levels, partially offset by higher variable costs.
- Teknova launched the Fill-Tek™ Dispensing System, providing customers flexibility to order single-use bag sizes, quantities, and fill volumes across RUO, RUO+, and GMP grades.
Concerns
- Teknova reported a net loss of $3.5 million and a loss from operations of $3.2 million in the third quarter 2026.
- Operating expenses increased to $8.0 million from $7.2 million, primarily reflecting higher sales and marketing spending from higher headcount and slightly increased general and administrative expenses.
- The company continued to report Free Cash Outflow, at $1.4 million for the third quarter 2026.
- Forward-looking risks identified by the company include demand delays or pauses in customer orders, cash flows and revenue growth rate, supply chain, sourcing, manufacturing, warehousing, and inventory management.
What to watch
- Execution against fiscal 2026 total revenue guidance of $46 million to $48 million.
- Whether full-year Free Cash Outflow remains less than $8 million.
- Sustainability of increased custom-product purchases by small and mid-sized biotech customers and associated contract manufacturers.
- Whether gross-margin benefits from higher revenue and inventory-related fixed-cost absorption continue amid higher variable costs.
- Deployment of the approximately $42.9 million in net proceeds from the October 2026 public offering.
Balance sheet and cash flow
- Total cash and short-term investments were $16.6 million and total borrowings were $13.2 million at the end of the third quarter 2026.
- On October 22, 2026, Teknova closed an underwritten public offering of 9,200,000 shares of common stock at a public offering price of $5.00 per share, for gross proceeds of $46.0 million and net proceeds of approximately $42.9 million.
- Cash used in operating activities was $1.3 million for the third quarter 2026, compared to $2.0 million of cash used in operating activities for the third quarter 2025.
- Free Cash Outflow was $1.4 million for the third quarter 2026, compared to $2.4 million for the third quarter 2025.
Analysis
Teknova reported third-quarter total revenue of $12.7 million, up 22% from $10.5 million in the prior-year quarter. Lab Essentials revenue was $9.0 million, up 9%, while Clinical Solutions revenue was $3.2 million, up 86%. Management attributed growth to increased sales to life science tools and diagnostics and biopharma customers, alongside increased custom-product purchases by small and mid-sized biotech customers and their associated contract manufacturers.
Profitability improved on the higher revenue base. Gross profit was $4.8 million versus $3.2 million, and gross margin rose to 38.0% from 30.7%. The company said the margin improvement was primarily driven by higher revenue and, to a lesser extent, lower fixed cost absorption into cost of goods sold from changes in finished-goods inventory levels, partly offset by higher variable costs. Total operating expenses increased to $8.0 million from $7.2 million, led by higher sales and marketing headcount and slightly increased general and administrative expense.
Losses and cash outflow narrowed. Net loss was $3.5 million, or negative $0.06 per diluted share, compared with $4.3 million, or negative $0.08 per diluted share. Adjusted EBITDA was negative $1.0 million versus negative $1.6 million. Cash used in operating activities was $1.3 million and Free Cash Outflow was $1.4 million, compared with $2.0 million and $2.4 million, respectively, in the prior-year quarter.
The company raised fiscal 2026 revenue guidance to $46 million to $48 million and reaffirmed its expectation for Free Cash Outflow of less than $8 million. At quarter-end, total cash and short-term investments were $16.6 million and total borrowings were $13.2 million. Subsequent to quarter-end, Teknova completed a public offering that generated gross proceeds of $46.0 million and net proceeds of approximately $42.9 million, strengthening balance-sheet flexibility while the company continues to fund operations and growth initiatives.
Management, verbatim
We posted record revenue for the second consecutive quarter.
Stephen Gunstream, President and Chief Executive Officer
Growth was driven by increased sales of products to life science tools and diagnostics, and to biopharma customers.
Stephen Gunstream, President and Chief Executive Officer
We delivered excellent financial results in the third quarter 2026 compared to 2025, highlighted by 22% revenue growth and a significant improvement in Adjusted EBITDA and Free Cash Outflow.
Matt Lowell, Chief Financial Officer
Not in the filing
stated, not guessed- Previous-release outlook was not provided, so comparison of actual results with prior guidance is unavailable.
- Sequential revenue, segment revenue, margin, earnings, and cash-flow comparisons were not reported.
- Fiscal 2026 guidance for gross margin, operating expenses, tax rate, EPS, Adjusted EBITDA, and cash balance was not provided.
- Dividend and share-repurchase activity was not reported.
- A GAAP operating-income figure was not reported because the company reported loss from operations.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Alpha Teknova (Nasdaq: TKNO) filed an 8‑K reporting Q3 2026 results and an upward revision to its full‑year revenue outlook.
Ticker impact
Alpha Teknova raised its 2026 revenue guidance to $46-48 million and reported Q3 revenue of $12.7 million, up 22% YoY.
likely upward pressure as the market prices in the raised guidance
The company disclosed a material increase in revenue guidance and a strong quarterly revenue beat, which are fresh primary facts that can move the share price.
Market effects
Positive outlook for the life‑science reagents sector may boost peers with similar product lines.
Limited to U.S. small‑cap biotech/life‑science niche.
Minimal global impact beyond sector sentiment.
Counterpoint
If the raised guidance is already priced in, the stock could face short‑term profit‑taking.
Key entities
- ExecutiveStephen Gunstream
President and CEO who commented on the revenue growth.
- ExecutiveMatt Lowell
Chief Financial Officer who highlighted the guidance raise.
